Precision ApS
Key figures
- Return on assets
- –
- Return on equity
- -5.3%
- Current ratio
- 62.8%
- Equity ratio
- 88.5%
Profit and loss
| Reporting period | |
|---|---|
Gross profit | -895,254 |
Finance expenses | 69,781 |
Tax expense | 0 |
Profit/loss for the year | -965,035 |
Employees
| Reporting period | |
|---|---|
Avg. employees | 0 |
Balance sheet
| Reporting period | |
|---|---|
Cash and cash equivalents | 1,294,352 |
Current assets | 1,479,539 |
Non-current assets | 19,007,331 |
Total assets | 20,486,870 |
Equity | 18,129,328 |
Liabilities | 2,357,542 |
Current liabilities | 2,357,542 |
Working capital
| Reporting period | |
|---|---|
Other current receivables | 185,187 |
Trade payables | 153,880 |
Capital and dividend
| Reporting period | |
|---|---|
Contributed capital | 81,524 |
Retained earnings | 18,047,804 |
Investments and assets
| Reporting period | |
|---|---|
Long-term investments and receivables | 19,007,331 |
Annual report highlights
Business and development
The purpose of the company is to operate as an investment business and engage in related activities, as well as to serve as a holding company for subsidiaries.
Risks and material matters
The Company’s subsidiary, 2cureX A/S, has incurred losses and is dependent on additional financing to continue its operations. 2cureX A/S incurred a loss of DKK 17.5 million in 2025 and had negative equity of DKK 0.2 million at 31 December 2025. 2cureX A/S’ continued operations depend on additional financing, including completion of a planned transaction and related convertible loan financing. These matters are subject to conditions outside 2cureX A/S’ control, and therefore a material uncertainty exists that may cast significant doubt on 2cureX A/S’ ability to continue as a going concern.Precision ApS has issued a letter of financial support to 2cureX A/S, valid until the annual report of 2cureX A/S for 2026 has been approved and published. Management expects that 2cureX A/S will obtain …
The Company’s investment in its subsidiary, 2cureX A/S, is recognised at DKK 19,007,331 at 31 December 2025. Investments in subsidiaries are measured at cost or, where cost exceeds the recoverable amount, at this lower value.The recoverable amount of the investment depends on 2cureX A/S’ ability to continue as a going concern and to complete the planned financing described in Note 1. Management has assessed that no impairment is required at 31 December 2025.However, due to the material uncertainty regarding 2cureX A/S’ ability to continue as a going concern, there is uncertainty relating to the recognition and measurement of the investment. If 2cureX A/S is unable to complete the planned financing or continue its operations, the investment may not be recoverable in full, and a material impairment loss may be required.
Commitments and security
Other contingent liabilities
The Company has issued a letter of support for its subsidiary, 2cureX A/S, which will remain valid until the subsidiary's statutory financial statements for 2026 are approved.…
Create a free account to see up to 9 years of financial history
Create free account